VIVA Biotech Holdings
HKEX:1873
Income Statement
Earnings Waterfall
VIVA Biotech Holdings
Revenue
|
2.2B
CNY
|
Cost of Revenue
|
-1.4B
CNY
|
Gross Profit
|
738.4m
CNY
|
Operating Expenses
|
-527.4m
CNY
|
Operating Income
|
211.1m
CNY
|
Other Expenses
|
-327.2m
CNY
|
Net Income
|
-116.1m
CNY
|
Income Statement
VIVA Biotech Holdings
Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue |
697
N/A
|
1 526
+119%
|
2 104
+38%
|
2 186
+4%
|
2 380
+9%
|
2 413
+1%
|
2 156
-11%
|
|
Gross Profit | ||||||||
Cost of Revenue |
(392)
|
(1 005)
|
(1 453)
|
(1 507)
|
(1 564)
|
(1 536)
|
(1 417)
|
|
Gross Profit |
305
N/A
|
521
+71%
|
651
+25%
|
680
+4%
|
816
+20%
|
877
+7%
|
738
-16%
|
|
Operating Income | ||||||||
Operating Expenses |
(215)
|
(335)
|
(391)
|
(431)
|
(520)
|
(556)
|
(527)
|
|
Selling, General & Administrative |
(123)
|
(219)
|
(320)
|
(384)
|
(404)
|
(410)
|
(410)
|
|
Research & Development |
(66)
|
(81)
|
(92)
|
(96)
|
(136)
|
(172)
|
(128)
|
|
Other Operating Expenses |
(26)
|
(34)
|
22
|
48
|
20
|
25
|
10
|
|
Operating Income |
90
N/A
|
186
+108%
|
260
+40%
|
249
-4%
|
295
+19%
|
321
+9%
|
211
-34%
|
|
Pre-Tax Income | ||||||||
Interest Income Expense |
92
|
42
|
(59)
|
(253)
|
(715)
|
(627)
|
(434)
|
|
Non-Reccuring Items |
9
|
4
|
9
|
6
|
(50)
|
(53)
|
(8)
|
|
Total Other Income |
(547)
|
55
|
137
|
161
|
10
|
0
|
174
|
|
Pre-Tax Income |
(356)
N/A
|
288
N/A
|
348
+21%
|
162
-53%
|
(459)
N/A
|
(359)
+22%
|
(56)
+84%
|
|
Net Income | ||||||||
Tax Provision |
(23)
|
(41)
|
(47)
|
(43)
|
(45)
|
(46)
|
(44)
|
|
Income from Continuing Operations |
(379)
|
247
|
301
|
120
|
(504)
|
(405)
|
(100)
|
|
Income to Minority Interest |
(8)
|
(19)
|
(13)
|
(8)
|
(24)
|
(31)
|
(16)
|
|
Net Income (Common) |
(387)
N/A
|
228
N/A
|
288
+26%
|
111
-61%
|
(528)
N/A
|
(436)
+17%
|
(116)
+73%
|
|
EPS (Diluted) |
-0.25
N/A
|
0.13
N/A
|
0.14
+8%
|
0.05
-64%
|
-0.28
N/A
|
-0.23
+18%
|
-0.06
+74%
|